PeerVoice Oncology & Haematology Audio

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Oncology & Haematology that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

156 episodes

22d ago latest

fortnightly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/oncology_audio.xml

Episodes 157

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers
2d ago · 30:10
For the complete activity, including supporting material, please visit https://www.peervoice.com/EMH860. Presented by Giannis Mountzios, MD, PhD. Learning Objectives: Recall the results of pivotal clinical trials evaluating the role of Delta-like ligand 3 (DLL3)-targeted T-cell engagers in the treatment of extensive-stage small-cell lung cancer (ES-SCLC); Identify patients presenting with progressive ES-SCLC who may benefit from treatment with a DLL3-targeted therapy; Provide DLL3-targeted therapy appropriately, considering factors such as timing of dosing and recommended premedication and ste
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
2d ago · 1:01:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/TNJ860. Presented by Jeffrey Weitz, MD, OC, FRCP(C); Charlotte Cordonnier, MD, PhD; and Mike Sharma, MD, MSc, FRCPC. Learning Objectives: Describe the rationale for FXIa inhibition for reducing the risk of secondary stroke, including the relative importance of this coagulation factor in haemostasis, thrombosis and real-world data from people living with high/low levels of FXIRecall the results of clinical trials evaluating FXIa inhibitors for secondary stroke prevention after non-cardioembolic isch
Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes
15d ago · 32:12
For the complete activity, including supporting material, please visit https://www.peervoice.com/KGV860. Presented by Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP; Amer Durrani, FRCS (Plast); and Philip Albery, LLB. Learning Objectives: Identify the unmet needs in the management of high-risk cutaneous squamous cell carcinoma (CSCC), including the challenges and morbidity associated with existing interventions; Assess patient preferences and quality-of-life considerations when making treatment decisions, including the impact on physical and mental wellbeing; Evaluate data from tri
Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes
22d ago · 1:20:49
For the complete activity, including supporting material, please visit https://www.peervoice.com/PMG860. Presented by Meletios Dimopoulos, MD; Eilidh Duncan, PhD; Monique Minnema, MD, PhD and Fredrik Schjesvold, MD, PhD. Learning Objectives: Recognise unmet needs experienced by patient populations diagnosed with NDMM, including patient- and clinician-level barriers to shared decision-making; Recall clinical trial data evaluating the safety and efficacy of guideline-recommended treatment approaches for the front-line management of NDMM; Formulate individualised treatment plans for the managemen
One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings
1mo ago · 26:33
For the complete activity, including supporting material, please visit https://www.peervoice.com/GVP860. Presented by Miguel Bajouco, MD, MSc; David Cassiman, MD, PhD; Rebecca Karp Leaf, MD; Katherine Pocius, MD, MPH; and Paulo Lima Serrano, MD, PhD Learning Objectives: Recognise the importance of early suspicion of acute hepatic porphyria (AHP) in reducing diagnostic delays and improving outcomes; Explain how to test for AHP in patients with indicative clinical symptoms and signs; Analyse presenting symptoms and clinical history to determine when AHP should be strongly suspected and diagnosti
Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative
2mo ago · 21:06
For the complete activity, including supporting material, please visit https://www.peervoice.com/QZY860. Presented by Andrea Necchi, MD and Melanie Costin. . Learning Objectives: Recognise the benefits of implementing shared decision-making when managing patients with more advanced stages of bladder cancer, including muscle-invasive bladder cancer (MIBC) and locally advanced or metastatic urothelial carcinoma (la/mUC); Implement recommended patient communication and empowerment techniques to encourage greater understanding of available treatment options among patients with MIBC or la/mUC.
Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge
2mo ago · 18:45
For the complete activity, including supporting material, please visit https://www.peervoice.com/TPE860. Presented by Silvia Stacchiotti, MD and Michiel van de Sande, MD, PhD. Learning Objectives: Describe the clinical evidence supporting emerging systemic therapies for tenosynovial giant cell tumour (TGCT); Identify factors that influence decisions on whether to opt for systemic treatment versus surgical intervention; Analyse case scenarios to propose evidence-based treatment plans for patients with TGCT.
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
2mo ago · 19:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/CFH860. Presented by Javier Cortés, MD, PhD and Laura Huppert, MD. Learning Objectives: Recall the results of clinical trials evaluating TROP2-directed antibody-drug conjugates (ADCs) as monotherapy or in combination with a PD-1 inhibitor in frontline treatment settings of HR+/HER2- or triple-negative metastatic breast cancer (TNBC); Assess the potential clinical impact of these data, including patient populations included in trials and how these relate to patients seen in the real-world clinic..
Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings
3mo ago · 28:23
For the complete activity, including supporting material, please visit https://www.peervoice.com/GSD860. Presented by Marwan Fakih, MD; Aparna R. Parikh, MD, MS, FASCO; and Jenna Scott. Learning Objectives: Identify practical strategies that support timely detection of progression, preservation of performance status, and early planning of treatment sequencing to maximize receipt of multiple lines of active therapy for mCRC; Apply principles of shared clinical decision-making to individualize the design and sequencing of later-line treatment regimens in individuals with mCRC who have progressed
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
3mo ago · 54:23
For the complete activity, including supporting material, please visit https://www.peervoice.com/UGY860. Presented by Trisha Wise-Draper, MD, PhD; Christine H. Chung, MD; Renata Ferrarotto, MD; and Kevin Harrington, PhD, FRCP, FRCR. Learning Objectives: Explain the implications of human papillomavirus (HPV) status in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) for patient outcomes and quality of life; Interpret clinical trial data stratified by HPV status to identify limitations of current standard-of-care therapies for non-HPV–associated recurrent/metastatic HNSCC; Expl
Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
3mo ago · 29:59
For the complete activity, including supporting material, please visit https://www.peervoice.com/QYU860. Presented by Martin Köbel, MD and Diana N. Ionescu, MD, MSc (EMMP). Learning Objectives: Explain the staining pattern of FRα-positive in tubo-ovarian and peritoneal high-grade serous carcinoma; Score the intensity and distribution of FRα expression in histology section of tubo-ovarian and peritoneal high-grade serous carcinoma; Discuss the implications of immunohistochemistry assessment of tubo-ovarian and peritoneal high-grade serous carcinoma for FRα expression on the subsequent course of
Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
5mo ago · 20:07
For the complete activity, including supporting material, please visit https://www.peervoice.com/RKZ860. Presented by Pier Luigi Zinzani, MD, PhD. Learning Objectives: Recall signs, symptoms, and outcomes associated with idiopathic multicentric Castleman disease (iMCD) and how these relate to other conditions with similar clinical features; Implement evidence-based best practice approaches to the diagnostic evaluation of patients where iMCD is suspected; Formulate appropriate treatment plans for patients diagnosed with iMCD.
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
5mo ago · 29:29
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving and sustaining terminal complement inhibition in patients with paroxysmal nocturnal haemoglobinuria (PNH), and the evidence for C5 inhibitor therapy on key efficacy outcomes; Recognise that extravascular haemolysis (EVH) is a potential limitation of terminal complement inhibition with C5 inhibitors and the need to target proximal complement blockade in patie
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
5mo ago · 40:01
For the complete activity, including supporting material, please visit https://www.peervoice.com/KBA860. Presented by Jonathan W. Goldman, MD and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guideline recommendations for the use of immunotherapy in small cell lung cancer (SCLC); Evaluate the rationale, evidence, and implications of emerging strategies for treatment of extensive-stage (ES)-SCLC, including use of combination therapy in the maintenance phase of first-line treatment; Identify relevant patient and disease-specific considerations that may gu
Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More
6mo ago · 28:24
For the complete activity, including supporting material, please visit https://www.peervoice.com/AHU860. Presented by Matthew J. Koster, MD and Carmelo Gurnari, MD, PhD. Learning Objectives: Identify and distinguish the clinical presentation of VEXAS syndrome from other systemic inflammatory diseases; Describe the role of UBA1 mutations and resultant ubiquitination defects in the pathogenesis of VEXAS syndrome; Utilise practical approaches to identify and evaluate patients with suspected VEXAS syndrome to facilitate timely and accurate diagnosis including appropriate genetic testing for UBA1 m
Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
6mo ago · 19:34
For the complete activity, including supporting material, please visit https://www.peervoice.com/GNV860. Presented by Cristina Saura Manich, MD, PhD and Aditya Bardia, MD. Learning Objectives: Evaluate the clinical data for emerging therapeutic strategies for the management of HER2+ metastatic breast cancer in the first-line setting; Discuss key learnings from clinical trials for investigative first-line treatment approaches for HER2+ metastatic breast cancer in context of different patient and disease characteristics.
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
7mo ago · 21:47
Visit https://www.peervoice.com/CCM860 to view the entire programme with slides. After completing “Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings”, participants will be able to: Explain the mechanistic rationale for investigating the therapeutic potential of TROP2-targeted treatment approaches in early treatment and disease-stage settings for triple-negative breast cancer (TNBC); Differentiate between TROP
Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target
8mo ago · 19:41
Visit https://www.peervoice.com/FCE860 to view the entire programme with slides. After completing “Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target”, participants will be able to: Recall the cellular role of p53 in regulating apoptosis, and how this is disrupted in patients with myelofibrosis; and Assess the clinical significance of trial data evaluating the safety and efficacy of MDM2 inhibition (as monotherapy or in combination with other agents) in the therapeutic management of patients with TP53-wt myelofibrosis.
Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy
8mo ago · 20:07
Visit https://www.peervoice.com/MQC860 to view the entire programme with slides. After completing “Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy”, participants will be able to: Recognize unmet needs surrounding the management of peripheral T-cell lymphoma (PTCL), including the impact of the disease on patient quality of life (QoL); Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatments for the management of relapsed/refractory (R/R) PTCL; and Imp
Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025
9mo ago · 19:52
Visit https://www.peervoice.com/USJ860 to view the entire programme with slides. After completing “Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025”, participants will be able to: Describe recent clinical trial data on novel targeted therapies for HER2-mutant NSCLC; and Evaluate recent clinical trial data on novel HER2-targeted therapies within the wider treatment landscape of NSCLC.
Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO
10mo ago · 22:21
Visit https://www.peervoice.com/YHE860 to view the entire programme with slides. After completing “Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO”, participants will be able to: Evaluate emerging updates on antibody-drug conjugates (ADCs) for the treatment of HER2+ breast cancer; Recall the latest evidence for ADCs in the treatment of HR+ and/or triple-negative breast cancer; and Assess the implications of the latest clinical evidence for approved ADCs in breast cancer in context of current treatment guidelines.
Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
10mo ago · 21:10
Visit https://www.peervoice.com/XKC860 to view the entire programme with slides. After completing “Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC”, participants will be able to: Evaluate novel data presented at ESMO 2025 related to the use of androgen receptor pathway inhibitors (ARPIs) in the management of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), including relevant efficacy and safety data, subgroup analyses, and real-world evi
Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies
10mo ago · 36:59
Visit https://www.peervoice.com/EAJ860 to view the entire programme with slides. After completing “Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies”, participants will be able to: Recognize guideline-recommended best practices in the diagnostic assessment and therapeutic management of patients presenting with blastic plasmacytoid dendritic cell neoplasm (BPDCN); Implement evidence-based best practice approaches to the diagnosis of BPDCN in patients presenting with symptoms of this condition; and Formulate app
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
11mo ago · 1:01:14
Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish betwe
Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients
11mo ago · 30:05
Visit https://www.peervoice.com/DHX860 to view the entire programme with slides. After completing “Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients”, participants will be able to: Implement recommended patient communication approaches when discussing mutational testing in metastatic castration-resistant prostate cancer (mCRPC), including what tests involve, what impact a positive result means for treatment options, and how to empower patients to make informed decisions about their treat

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Oncology & Haematology Audio

Episodes 157

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers

Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025

Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO

Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC

Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Video

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Clinical Pharmacology Audio

PeerVoice Endocrinology & Metabolic Disorders Video

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 157

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers

Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025

Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO

Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC

Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients